Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating activities
Net loss	$ (16,414,159)	$ (16,461,178)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of assets	0	362,949
Impairment loss	0	187,500
Depreciation and amortization	494,232	859,487
Stock-based compensation expense	884,943	2,174,627
Gain on extinguishment of debt	0	(17,974)
Deferred rent	0	59,206
Change in fair value of derivative financial instruments—warrants	(28,188)	(617,072)
Release of clinical trial funding commitment	703,327	0
Changes in operating assets and liabilities:
Other assets	(54,778)	(23,755)
Accounts receivable and unbilled receivable	(35,725)	19,262
Prepaid expenses	115,459	21,451
Operating lease right-of-use assets	302,491	0
Accounts payable and accrued expenses	1,455,336	214,484
Operating lease liabilities	(776,806)	0
Other liabilities	86,368	22,000
Net cash used in operating activities	(13,267,500)	(13,199,013)
Investing activities
Capital expenditures	(67,622)	(5,100)
Proceeds from disposals of capital equipment	0	27,942
Purchases of short-term investments	0	(31,500)
Sales of short-term investments	0	31,500
Net cash provided (used) by investing activities	(67,622)	22,842
Financing activities
Proceeds from sale of common stock and warrants, net of expenses of $158,678 and $1,336,123 respectively	8,817,772	11,779,525
Proceeds from sales of Series B Convertible Preferred Stock, net of expenses of $0 and $497,617 respectively	0	4,386,762
Costs related to the clinical trial funding commitment	(40,000)	0
Proceeds from exercise of warrants	3,299,509	1,612,667
Repayments under equipment line of credit	0	(1,200,033)
Payment upon debt extinguishment	0	(175,381)
Net cash provided by financing activities	12,077,281	16,403,540
Net change in cash and cash equivalents	(1,257,841)	3,227,369
Cash and cash equivalents—Beginning of period	11,453,133	8,225,764
Cash and cash equivalents—End of period	10,195,292	11,453,133
Supplementary disclosure of cash flow activity:
Cash paid for taxes	800	800
Cash paid for interest	0	22,482
Supplemental disclosure of non-cash investing and financing activities:
Preferred stock dividend payable on Series A Convertible Preferred Stock	24,240	24,240
Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640	1,675,000	0
Series B Convertible Preferred Stock
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend recognized on beneficial conversion features of convertible preferred stock	0	2,769,533
Common stock issued upon conversion of Convertible Preferred Stock	0	886
Series C Convertible Preferred Stock
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend recognized on beneficial conversion features of convertible preferred stock	268,269	0
Common stock issued upon conversion of Convertible Preferred Stock	$ 33	$ 0